Silence Therapeutics Announces CMO Departure, Appoints Interim
Ticker: SLNCF · Form: 8-K · Filed: Dec 15, 2025 · CIK: 1479615
| Field | Detail |
|---|---|
| Company | Silence Therapeutics PLC (SLNCF) |
| Form Type | 8-K |
| Filed Date | Dec 15, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, personnel
TL;DR
CMO out, interim in at Silence Therapeutics. Watch the pipeline.
AI Summary
Silence Therapeutics plc announced on December 14, 2025, the departure of its Chief Medical Officer, Dr. Anish Surpur. The company also reported the appointment of Dr. Gareth Jenkins as interim Chief Medical Officer. This filing also includes information regarding compensatory arrangements for certain officers and regulation FD disclosures.
Why It Matters
A change in key executive leadership, especially the Chief Medical Officer, can signal shifts in the company's strategic direction and drug development pipeline.
Risk Assessment
Risk Level: medium — Executive departures, particularly in critical roles like CMO, can introduce uncertainty regarding the company's future strategy and operational stability.
Key Players & Entities
- Silence Therapeutics plc (company) — Registrant
- Dr. Anish Surpur (person) — Departing Chief Medical Officer
- Dr. Gareth Jenkins (person) — Appointed Interim Chief Medical Officer
- December 14, 2025 (date) — Date of earliest event reported
FAQ
Who has been appointed as the interim Chief Medical Officer?
Dr. Gareth Jenkins has been appointed as the interim Chief Medical Officer.
When was the earliest event reported in this filing?
The earliest event reported was on December 14, 2025.
What is the company's primary business sector?
Silence Therapeutics plc is in the Pharmaceutical Preparations sector (SIC code 2834).
What is the company's principal executive address?
The company's principal executive address is 12 Hammersmith Grove, London, United Kingdom, W6 7AP.
What items are being reported in this 8-K filing?
This filing reports on the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, Regulation FD Disclosure, and Financial Statements and Exhibits.
Filing Stats: 1,143 words · 5 min read · ~4 pages · Grade level 11.5 · Accepted 2025-12-15 16:01:25
Filing Documents
- sln-20251214.htm (8-K) — 65KB
- sln-ex99_1.htm (EX-99.1) — 16KB
- 0001193125-25-319156.txt ( ) — 236KB
- sln-20251214.xsd (EX-101.SCH) — 55KB
- sln-20251214_htm.xml (XML) — 6KB
01 Exhibits
Item 9.01 Exhibits. Exhibit Number Description 99.1 Press Release dated December 15, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Silence Therapeutics plc Date: December 15, 2025 By: /s/ Rhonda Hellums Name: Rhonda Hellums Title: Chief Financial Officer